FDA Requests More Restrictions on Ovarian Cancer Drugs

The limits on second-line prescribing for one of the drugs, rucaparib, could put the company's financial future at risk, a company report shows.
Medscape Medical News

source https://www.medscape.com/viewarticle/984547?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?